Holen Sie sich die Stockscreener-App
0.8479
4.72%
-0.042
Handel nachbörslich:
.83
-0.0179
-2.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TPST?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8899
Offen:
$0.8688
24-Stunden-Volumen:
2.95M
Relative Volume:
0.97
Marktkapitalisierung:
$21.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.11M
KGV:
-0.3563
EPS:
-2.38
Netto-Cashflow:
$-28.18M
1W Leistung:
-22.92%
1M Leistung:
-22.92%
6M Leistung:
-73.34%
1J Leistung:
-75.49%
1-Tages-Spanne:
$0.80
$0.88
1-Wochen-Bereich:
$0.80
$1.16
52-Wochen-Spanne:
$0.80
$6.00
Tempest Therapeutics Inc Stock (TPST) Company Profile
Firmenname
Tempest Therapeutics Inc
Sektor
Branche
Telefon
415-798-8589
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie TPST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TPST | 0.8479 | 21.18M | 0 | -31.11M | -28.18M | -2.38 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten
William Blair Has Negative Estimate for TPST FY2024 Earnings - Defense World
Research Analysts Offer Predictions for TPST FY2024 Earnings - Defense World
TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles - Investing.com Canada
HC Wainwright Reiterates “Buy” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler - TipRanks
TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tempest Therapeutics advances liver cancer drug to Phase 3 trial By Investing.com - Investing.com Canada
Tempest Therapeutics reports Q3 EPS (41c), consensus (36c) - TipRanks
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest Therapeutics advances liver cancer drug to Phase 3 trial - Investing.com
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 - GlobeNewswire
Tempest Gets FDA Green Light for Pivotal Phase 3 Liver Cancer Drug Trial | TPST Stock | TPST Stock News - StockTitan
Tempest Therapeutics (TPST) Stock Jumps 83% On FDA Phase 3 Trial News - Barchart
TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK
Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex
TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com
Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa
TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com
Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News
Tempest Therapeutics Inc [TPST] Stock trading around $1.10 per share: What’s Next? - The DBT News
Tempest Therapeutics Inc [NASDAQ: TPST] Sees Decrease in Stock Value - Knox Daily
Tempest Therapeutics shares retain Buy rating post Roche deal - Investing.com
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a -18.52 Decrease, Closing at 1.10 - The Dwinnex
Tempest Therapeutics shares retain Buy rating post Roche deal By Investing.com - Investing.com UK
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Fluctuations - The InvestChronicle
TPST’s price-to-free cash flow ratio: What it means for investors - US Post News
Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study - XM
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell - Marketscreener.com
Tempest stock gains on Roche collaboration (NASDAQ:TPST) - Seeking Alpha
Tempest Therapeutics partners with Roche on cancer trial - Investing.com
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - ForexTV.com
Tempest Therapeutics, Inc Enters into Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd. to Which Roche Will Supply Roche?S Atezolizumab - Marketscreener.com
Tempest Extends Limited Duration Stockholder Rights Plan - GlobeNewswire
Tempest Announces Agreement with Roche to Support - GlobeNewswire
Healthy Upside Potential: Tempest Therapeutics Inc (TPST) - SETE News
TPST Shares Experience Surge in Value - Knox Daily
How to interpret Tempest Therapeutics Inc (TPST)’s stock chart patterns - US Post News
Scotiabank initates Tempest Therapeutics Inc (TPST) rating to a Sector outperform - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Tempest Therapeutics Inc (TPST) - The Dwinnex
Sigourney Weaver to star in Jamie Lloyd's 'The Tempest' this fall - LondonTheatre.co.uk
A Closer Look at Tempus AI Inc. (TEM) Stock Gains - The InvestChronicle
The Tempest cast announced to join Sigourney Weaver at the Theatre Royal Drury Lane in London - WestEndTheatre.com
See Who's Joining Sigourney Weaver in West End The Tempest - Playbill
Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM) - MarketBeat
Full Cast Announced for The Tempest at Theatre Royal Drury Lane - London Theatre 1
Finanzdaten der Tempest Therapeutics Inc-Aktie (TPST)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):